ArticleDiscover oncology2025
A histone acetylation score for prognostic stratification and immunogenomic profiling in esophageal cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimTo investigate the prognostic significance of histone acetylation (HAc) regulators in esophageal cancer (EC) and develop a transcriptome-based HAc_score reflecting epigenetic and immunogenomic states.
methodsExpression and mutation from EC were analyzed to identify prognostic HAc regulators via univariable Cox models. Consensus clustering defined HAc-related expression patterns. Differentially expressed genes (DEGs) among clusters were functionally enriched. A principal component-based HAc_score was constructed from prognostic DEGs and tested for associations with overall survival, tumor mutational burden (TMB), immunophenoscore (IPS), and immune cell infiltration.
resultsThree HAc-related expression patterns showed distinct biological and immune features. From shared DEGs, 19 prognostic genes defined two molecular subtypes and served as the basis for the HAc_score. Higher HAc_score was associated with better overall survival, particularly in early-stage disease. HAc_score correlated inversely with TMB and positively with IPS components, suggesting a transcriptionally active, immunogenic phenotype despite lower mutation burden. Combining HAc_score with TMB improved risk stratification.
conclusionHAc_score quantifies HAc–linked transcriptional states in EC and reflects tumor–immune interactions. It stratifies survival risk and complements TMB, supporting its potential use as a prognostic biomarker and integrative epigenetic–immune signature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.